OBJECTIVES: Although homografts are often the preferred valve conduits for right ventricular outflow tract (RVOT) reconstruction, data on long-term homograft-related outcomes, durability and impact on quality of life (QoL) are scarce. The aim of this study was therefore to describe the long-term homograft function, clinical outcomes and QoL after RVOT reconstruction. METHODS: We performed a single-centre retrospective analysis of all consecutive patients who underwent RVOT reconstruction with a homograft. Multiple subsequent allografts in the same patients were regarded as separate subjects. Valve-related events were analysed by Kaplan-Meier and Life Table methods. Serial echocardiographic measurements were analysed with mixed effects models. In addition, QoL was repeatedly assessed and compared with a matched general population. RESULTS: In total, 701 consecutive homografts were implanted in 604 patients [59.6% males, mean age at operation 19.5 ± 15.2 (standard deviation)]. Hospital mortality was 3.3%. After 25 years follow-up, survival and freedom from valve replacement were 84 ± 4% and 56 ± 6%, respectively. Freedom from valve replacement after 15 years for patients under 1 year of age was 28 ± 14% years, for those between 1 and 18 years, 59 ± 8%, and for those older than 18 years, 82 ± 5%. The peak gradient increased predominantly in the first postoperative decade in infants and paediatric patients from 19 to 54 mmHg. In adults, the average gradient increased from 9 to 31 mmHg after 14 years. Compared to a gender- and age-matched Dutch population, patients reported lower vitality and general health but less bodily pain. Patients, in whom QoL was repeatedly assessed, reported lower scores on physical functioning and vitality after a 5-year follow-up period. However, we found no differences in any of the subscales in patients who underwent valve replacement during the 5-year interval. CONCLUSIONS: Homografts are a durable valve alternative for RVOT reconstruction; in particular, adults show extensive freedom from valve replacement and report QoL comparable with healthy subjects. An online interactive application form created by our institution can be used to assess patient outcome after RVOT reconstruction with a homograft for different patient profiles.
OBJECTIVES: Although homografts are often the preferred valve conduits for right ventricular outflow tract (RVOT) reconstruction, data on long-term homograft-related outcomes, durability and impact on quality of life (QoL) are scarce. The aim of this study was therefore to describe the long-term homograft function, clinical outcomes and QoL after RVOT reconstruction. METHODS: We performed a single-centre retrospective analysis of all consecutive patients who underwent RVOT reconstruction with a homograft. Multiple subsequent allografts in the same patients were regarded as separate subjects. Valve-related events were analysed by Kaplan-Meier and Life Table methods. Serial echocardiographic measurements were analysed with mixed effects models. In addition, QoL was repeatedly assessed and compared with a matched general population. RESULTS: In total, 701 consecutive homografts were implanted in 604 patients [59.6% males, mean age at operation 19.5 ± 15.2 (standard deviation)]. Hospital mortality was 3.3%. After 25 years follow-up, survival and freedom from valve replacement were 84 ± 4% and 56 ± 6%, respectively. Freedom from valve replacement after 15 years for patients under 1 year of age was 28 ± 14% years, for those between 1 and 18 years, 59 ± 8%, and for those older than 18 years, 82 ± 5%. The peak gradient increased predominantly in the first postoperative decade in infants and paediatric patients from 19 to 54 mmHg. In adults, the average gradient increased from 9 to 31 mmHg after 14 years. Compared to a gender- and age-matched Dutch population, patients reported lower vitality and general health but less bodily pain. Patients, in whom QoL was repeatedly assessed, reported lower scores on physical functioning and vitality after a 5-year follow-up period. However, we found no differences in any of the subscales in patients who underwent valve replacement during the 5-year interval. CONCLUSIONS: Homografts are a durable valve alternative for RVOT reconstruction; in particular, adults show extensive freedom from valve replacement and report QoL comparable with healthy subjects. An online interactive application form created by our institution can be used to assess patient outcome after RVOT reconstruction with a homograft for different patient profiles.
Authors: Dietmar Boethig; Alexander Horke; Mark Hazekamp; Bart Meyns; Filip Rega; Joeri Van Puyvelde; Michael Hübler; Martin Schmiady; Anatol Ciubotaru; Giovanni Stellin; Massimo Padalino; Viktor Tsang; Ramadan Jashari; Dmitry Bobylev; Igor Tudorache; Serghei Cebotari; Axel Haverich; Samir Sarikouch Journal: Eur J Cardiothorac Surg Date: 2019-09-01 Impact factor: 4.191
Authors: Firdavs Oripov; Robert Ramm; Christine Falk; Tobias Goecke; Johannes Ebken; Ramadan Jashari; Dietmar Böthig; Alexander Horke; Murat Avsar; Dmitry Bobylev; Axel Haverich; Andres Hilfiker; Samir Sarikouch Journal: Front Cardiovasc Med Date: 2022-08-09
Authors: Pieter C van de Woestijne; Jamie L R Romeo; Ingrid van Beynum; Maarten Witsenburg; M Mostafa Mokhles; Ad J J C Bogers Journal: JTCVS Open Date: 2021-09-24
Authors: Xu Wang; Eleni-Rosalina Andrinopoulou; Kevin M Veen; Ad J J C Bogers; Johanna J M Takkenberg Journal: Eur J Cardiothorac Surg Date: 2022-09-02 Impact factor: 4.534
Authors: Jamie L R Romeo; Johanna J M Takkenberg; Judith A A E Cuypers; Natasha M S de Groot; Pieter van de Woestijne; Nico Bruining; Ad J J C Bogers; M Mostafa Mokhles Journal: Eur J Cardiothorac Surg Date: 2020-09-01 Impact factor: 4.191